Getein Biotech(SH:603387) Shang Hai Zheng Quan Bao·2025-11-21 20:03Core Viewpoint - The company held an online performance briefing for Q3 2025, discussing its operational and financial status, product developments, and addressing investor inquiries [1] Group 1: Company Performance and Strategy - As of the end of Q3 2025, the company's products have entered 67 countries and regions, obtaining nearly 3,300 product import licenses, indicating strong overseas market expansion [2] - The company reported a 30% year-on-year increase in chemical luminescence reagent testing volume, reflecting growing market recognition and the effectiveness of its strategy to drive reagent consumption through instrument installations [2][3] - The company achieved overseas revenue of 0.51 billion yuan in Q3 2025, a year-on-year increase of 47.34% and a quarter-on-quarter increase of 23.78% [2][4] Group 2: Product Development and Market Trends - The Metis7000 fully automated biochemical immunoassay line is designed for large hospitals, while the Metis6000 targets smaller laboratories, showcasing a complementary product matrix [3] - The company’s molecular POCT products are well-positioned to meet the rising demand for respiratory disease testing during the flu season, with significant product launches planned [2][4] - The company maintains a positive outlook on the future of its POCT product line, driven by policy support, technological advancements, and international market expansion [4] Group 3: Financial Management - The company successfully optimized its expenses, with total sales, management, and R&D expenses amounting to 368 million yuan, a decrease of 11.47% year-on-year [4] - The company is focused on enhancing resource allocation efficiency while ensuring stable business growth and necessary R&D investments [4]